KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Year Ended March 31, 2016; Provides Consolidated Earnings Guidance for the First Half of the Year Ending March 31, 2017 and Full Year Ending March 31, 2017
May 12, 2016
Share
KYORIN Holdings, Inc. reported consolidated earnings results for the year ended March 31, 2016. For the year, the company reported net sales of JPY 119,483 million compared to JPY 113,121 million a year ago. Operating income was JPY 19,636 million compared to JPY 14,737 million a year ago. Ordinary income was JPY 19,995 million compared to JPY 15,490 million a year ago. Profit attributable to owners of the parent was JPY 13,639 million compared to JPY 12,064 million a year ago. Net income per share was JPY 184.28 compared to JPY 161.63 a year ago. ROE was 8.9% compared to 8.4% a year ago. Cash flows from operating activities were JPY 11,137 million compared to JPY 6,391 million a year ago.
The company provided consolidated earnings guidance for the first half of the year ending March 31, 2017 and full year ending March 31, 2017. For the first half, the company expects net sales of JPY 53,900 million, operating income of JPY 3,900 million, ordinary income of JPY 4,200 million and profit attributable to owners of parent of JPY 3,000 million or JPY 40.72 per share.
For the year, the company expects net sales of JPY 120,000 million, operating income of JPY 14,500 million, ordinary income of JPY 14,900 million and profit attributable to owners of parent of JPY 10,700 million or JPY 145.23 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Year Ended March 31, 2016; Provides Consolidated Earnings Guidance for the First Half of the Year Ending March 31, 2017 and Full Year Ending March 31, 2017
KYORIN PHARMACEUTICAL CO., LTD. 
